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ABSTRACT 
International Journal of Exercise Science 13(2): 755-765, 2020. Objectives: Performance in running-
based sport depends on the ability to perform repetitive high intensity muscle contractions. Previous studies have 
shown that capsaicin analog (CAP) (i.e. Capsiate) supplementation may improve this performance. The purpose of 
this study was to investigate the acute effect of CAP supplementation on short (400 m) and middle distance (3000 
m) running time-trial performance, maximum heart rate (HR), and rate of perceived exertion (RPE). Methods: 
Twelve physically active men completed four randomized, double-blind trials: CAP condition (12 mg) or a placebo 
condition. Forty-five minutes after supplementation, the participants performed a 400- or 3000-meter running time 
trial. Time (in seconds) was recorded. HR was analyzed at rest and immediately post-exercise, and RPE was 
collected immediately after exercise. Results: For both the 400 m time-trial (CAP = 66.4 + 4.2 sec vs Placebo = 67.1 
+ 4.8 sec, p = 0.046) and the 3000 m time-trial (CAP = 893.9 ± 46.8 sec vs Placebo = 915.2 ± 67.6 sec, p = 0.015), the 
time in seconds was significantly less in the CAP compared to placebo conditions. There were no statistically 
significant differences for HR and RPE in any condition. Conclusion: In summary, acute CAP supplementation 
improved 400 m and 3000 m running time-trial performance in a distance-dependent way but without modifying 
the HR and RPE. 
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INTRODUCTION 
 
Capsaicin (8-methyl-N-vanillyl-trans-6-nonenamide), dihydrocapsaicin, nordihydrocapsaicin, 
homocapsaicin, and homodihydrocapsaicin constitute the capsaicinoids, which are bioactive 
phytochemicals found primarily in chili peppers, cayenne pepper, red pepper and other spicy 
foods. These phytochemicals are responsible for the fruit’s ‘pungent’ heat sensation (15). Their 
concentrations typically range from 0.1 mg/g in chili pepper to 2.5 mg/g in red pepper and 60 
mg/g in oleoresin red pepper. Additional capsaicin exists among the natural capsinoids 
(capsiate, dihydrocapsiate and nordihidrocapsiate), which are found in non-pungent Capsicums 
(Capsicum annuum L. or Capsicum frutescens L.), such as the pepper cultivar CH-19 sweet, 
were found to contain 0.22–20 mg total capsinoids/g of dry weight (19). They are structurally 
identical to the pungent constituents of Capsicum, i.e, capsaicin, dihydrocapsaicin, and 
nordihydrocapsaicin, respectively, though their ergogenic or therapeutic properties have not 
been as heavily investigated. The mean consumption of Capsicum spices in different cultures 
was reported to be 2.5 g/person/day in India, 5 g/person/day in Thailand (17) and 20 g/person 
per day in Mexico (12). Assuming a content of capsaicinoids in these spices of about 1%, the 
daily intake of capsaicinoids in these countries has been estimated to be 25–200 mg/person/day 
(4).  
 
Capsaicin and capsaicin analog, such as Capsiate (CAP) act through the Transient Receptor 
Potential Channel Vanilloid type-1 (TRPV1), a transmembrane channel expressed in many 
tissues, including the brain stem, mid-brain, hypothalamus, and limbic system centrally, and 
the gastrointestinal tract and adipose tissue peripherally (7). There is evidence that capsinoids 
possesses anti-obesity properties via reductions in appetite and energy intake (14). Although the 
mechanisms are not totally understood, it seems that it occurs through interactions with 
appetite-related hormones, such as an increase of GLP-1 (anorexigenic hormones) (22), as well 
as increased energy expenditure via activation of the sympathetic nervous system (7).  
 
Regarding the potential ergogenic effect of CAP, most studies have been conducted with rodents 
(8, 9, 23). Faraut et al. (8) investigated the effect of 14 days of CAP administration and verified 
an enhancement of aerobic ATP production attributable to UCP3 downregulation in rodent 
skeletal muscle. Yashiro et al. (23) demonstrated that 2 weeks of CAP resulted in a reduced 
oxidative cost of contraction in exercising mouse skeletal muscle. In addition, Kim et al. (10) 
demonstrated that 10 mg of capsaicin supplementation increased swimming endurance capacity 
(time to exhaustion), and the authors postulated that the increases in endurance performance 
were explained in part by an increase in plasma free fatty acids as a result of higher epinephrine 
release, thereby generating a glycogen sparing effect. Other potential mechanisms whereby 
capsaicin may improve performance could be related to TRVP1 activation in skeletal muscle, 
and subsequent increases in the release of calcium by the sarcoplasmic reticulum (13), inducing 
an enhanced interaction between actin-myosin filaments and greater force production (11). 
 
The ergogenic effects and mechanisms of CAP in humans are less known. Recently, a single dose 
of 12 mg CAP supplementation improved 1500-m running time-trial performance by 
approximately five seconds and decreased the rating of perceived exertion (RPE) in physically 
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active adults (6). Conversely, Opheim and Rankin (18) investigated the effect of 28.5 mg of 
cayenne pepper for 7 days on repeated-sprint exercise (15 x 30-m all-out sprints with 35-s rest 
intervals) in healthy athletes, however, the authors did not find significant benefits. 
Discrepancies between studies that may explain these divergent results include dose, the form 
of the pepper extract used (CAP vs. cayenne powder), duration (acute vs. chronic), and 
metabolic characteristics of the exercises employed. 
 
Considering that CAP enhances aerobic ATP production and decreases the oxidative cost of 
contraction in rodent skeletal muscle (23), it could be an ergogenic strategy to improve middle 
distance running time-trial performance (3000 m). Additionally, because capsaicin-mediated 
activation of the TRVP1 in skeletal muscle induces a larger calcium release and promotes an 
enhanced interaction between actin-myosin filaments and greater force production (11), it could 
also be efficient during exercises recruiting more type II fibers, such as a 400 m running. 
Therefore, the purpose of this study was to investigate the acute effect of capsaicin analog 
supplementation (Capsiate) on short (400 m) and middle distance (3000 m) running time-trial 
performance, maximum heart rate, and rating of perceived exertion in physically active adults 
and to compare the magnitudes of changes between distances. 
 
METHODS 
 
Participants 
Twelve physically active men were recruited (age = 28.6±5.4 y). The inclusion criteria for 
participation in the study were: between 18 and 35 years old; no participation in regimented 
running training during the previous six months; and not taken any supplements to improve 
performance during the 6 months prior to the tests. However, the participants practiced regular 
exercise, such as resistance training and jogging (less than three times a week and less than one 
hour per day). During the study, all participants were instructed not to consume any dietary 
supplements or ergogenic aids, as well as not to make any nutritional changes in their regular 
diet before each test. The study was approved by the Ethics Research Group of the Federal 
University of Piauí, Teresina, PI, Brazil (Protocol number: 3.169.545) and the research was 
conducted according to the 2013 Revision of the Declaration of Helsinki and all the participants 
signed an informed consent form about the purpose of the study and the possible risks. This 
research was carried out fully in accordance to the ethical standards of the International Journal 
of Exercise Science (16).   
 
Protocol 
This study used a randomized, double-blind, crossover design. Subjects completed six visits: on 
the first visit, measurements of anthropometrics and body composition were performed, and 
subjects completed one familiarization session on a treadmill and outdoor track. On the second 
visit, participants completed the maximal aerobic speed test. On the following four experimental 
trials, each participant consumed either the placebo or CAP in a counterbalanced design and 
then completed either a 400- or 3000-meter run performed at the same time of day (6:30 to 9 
AM), separated by one week, as illustrated in Figure 1. The time in seconds, maximum heart 
rate, and RPE was collected after exercise. 
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Figure 1. Experimental Design. 
 
Anthropometric and Body Composition Assessment: Subject stature (height) was measured 
with a Sanny brand stadiometer (Sanny, São Paulo, SP, Brazil) with precision of 0.1 cm and 
maximum length of 2.20 meters. Body weight was measured on an electronic scale (Filizola PL 
50; Filizola, Ltda., Brazil), with an accuracy of 0.1 kg. Fat mass and fat free mass in kilograms 
were assessed using bioelectrical impedance analysis and accompanying software (InBody S10, 
Gangnam-gu, Seoul, Korea). Participants wore light clothing, they were positioned in a supine 
position, and remained still throughout the examination. 
 
Maximal Aerobic Speed Test: Participants performed an incremental test on a treadmill (Evoque 
Jet-9, TRG Fitness, Blumenau, SC, Brazil) to volitional exhaustion. Initial treadmill velocity was 
set at 8.0 km.h-1 and increased by 1 km.h-1 per 2-min stage until the participant could no longer 
continue. Maximal velocity reached in the test was defined as the maximal aerobic speed (MAS). 
When the subject was not able to finish the last stage, speed was expressed according to the time 
of permanence in the last stage, determined as the following: MAS = velocity of penultimate 
stage + [(time, in seconds, remained at the last stage multiplied by 1 km.h-1)/60s]. 
 
Supplementation Protocol: Volunteers were instructed not to consume any spicy foods or add 
any spice to meals during the study, as well as not consume tea, coffee, alcoholic beverages, or 
stimulant beverages for a period of 12 hours before each test. Questionnaires were distributed 
to all participants to record food and fluid intake for 24 hours prior to each trial. Participants 
were instructed to eat their breakfast by eating healthy foods and replicate the same dietary 
intake as the first day in the subsequent trials. To ensure that food intake was similar between 
Int J Exerc Sci 13(2): 755-765, 2020 
International Journal of Exercise Science                                                          http://www.intjexersci.com 
759 
experimental trials, all food intakes were analyzed for total consumption of kilocalorie and 
macronutrients (Software - Dietpro version 52.8). The software used the database of the Brazilian 
food composition table (TACO) to calculate food consumption.  
 
In the exercise test sessions, each participant randomly consumed 2 capsules of Placebo (starch) 
or CAP with 6 mg per capsule, which were identical to ensure a double-blind design, 45 minutes 
before each experimental test. This time was selected because capsaicin reaches maximum 
concentrations within 45 minutes after ingestion, the half-life of capsaicin is approximately 25 
minutes and complete plasma clearance occurs approximately 105 minutes after ingestion (3). 
The product is standardized in 40% to 50% of Capsinoids (Capsiate) and the final product 
contained 50% in each 6 mg (Capsicum annuum L.) from India (Purifarma-Gemini 
Pharmaceutical Industry Ltda, Anapolis, GO, Brazil). The correction factor in assay calculation 
was used by Pharma Nostra (Campinas, Brazil) to guarantee 100% of capsinoids in each capsule, 
therefore, 12 mg total Capsiate was administrated. Finally, this dose was selected because the 
same product and dose improved performance in our previous studies with humans and none 
of the participants reported "hot" sensations or gastrointestinal discomforts (5, 6).  
 
Short and Middle-Distance Running Time-Trial Performance: Initially, participants completed 
one familiarization session to become acquainted with outdoor track. After seven days, 
participants performed a randomized short (400 m) or middle (3000 m) distance run on an 
outdoor track at Federal University of Piauí-PI, Brazil, separated by seven days. Prior to each 
testing session, participants completed a 5-minute warm-up (stretching and jogging). 
Participants were tested one at a time and were instructed to cover the distance in the shortest 
possible time, which was recorded using a polar stopwatch (V800, Polar Electro, Kempele, 
Finland). Participants were instructed to wear the same kind of clothes (light shorts, light t-
shirts, and running shoes) in each test. All tests were carried out on the same day at the same 
hour (6:30 to 9 AM), and all tests were conducted when the following climate values were 
presented: temperature (23-26°C), humidity (70-80%), pressure (1014-1016 mb), and wind speed 
(11-15 km.h-1). Four fitness professionals supervised all testing sessions and the volunteers 
maintained current activity but abstained from exercise the day before each trial.  
 
Heart Rate and Rating of Perceived Exertion: To measure resting heart rate, volunteers were 
instructed to remain in silence, awake, resting, spontaneously breathing, and lying down 
comfortably for five minutes using a polar stopwatch (V800, Polar Electro, Kempele, Finland). 
These procedures were performed before each trial and data were recorded in beats per minute 
(beats.min-1). The maximum heart rate was recorded also immediately post-exercise.  
 
The rating of perceived exertion (RPE) was measured after each exercise session using the 
OMNI-Walk/Run Scale ratings of perceived exertion (0-10 points) immediately after running 
time-trial.  
 
Statistical Analysis 
First, we performed a power analysis of this study based on the observation from a previous 
study that verified the effects of nitrate supplementation on exercise performance at moderate 
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and very-high simulated altitudes (21). The authors reported a mean difference of 64.8 sec for 3 
km time-trial and a standard deviation of 48.3 (19). When we used a type I error of 0.05 and 12 
subjects, according to PS software (version 3.1.2, Dupont and Plummer, 
http://biostat.mc.vanderbilt.edu/wiki/Main/PowerSampleSize), the power analysis 
computed was 0.98. 
 
Next, we verified via GraphPad software that one of the values was a significant outlier, thus 
this participant from the 3000 m condition was not included at final analysis. The data normality 
was verified using the Shapiro-Wilk test. Data are presented as means ± standard deviations, 
and the comparison of kilocalorie and macronutrients between trials were analyzed via a 
repeated measured ANOVA. The effect of CAP on the time-trial performance, maximum heart 
rate and rate of perceived exertion during short (400 m) and middle distance (3000 m) running 
were analyzed via a paired t test using the Statistical Package for Social Sciences 17.0 (SPSS Inc. 
Chicago, IL USA). Effect size was calculated via Cohen’s d, which describes the difference 
between the means normalized to the pooled standard deviation (SD) of the two groups, 
whereby a value of > 0.20 was considered small, > 0.50 moderate, and > 0.80 large. The 95% 
confidence intervals are also reported (CI 95%). 
 
RESULTS 
 
Table 1 presents the mean and standard deviation values for general sample characteristics and 
Table 2 shows the comparison of the dietary intake and macronutrient distribution 24 h prior to 
each trial. There were no statistically significant differences between conditions in both total and 
relative to body weight dietary intake and macronutrient distribution.  
 
We also compared the first and second attempt of each trial to verify the influence of the learning 
effect and there were no significant differences between first and second attempts in both 400 m 
(p = 0.906) and 3000 m (p = 0.896) trials.  
 
Table 1. General characteristics of the sample. 
Variables Mean ± SD (n = 12) 
Age (years) 28.6 ± 5.4 
Height (cm) 175.0 ± 5.4 
Weight (kg) 76.1 ± 8.4 
Fat mass (kg) 12.6 ± 6.7 
Fat free mass (kg) 63.6 ± 6.4 
MAS (km.h-1) 14.6 ± 0.7 
RPE 10 ± 0.5 
Maximum heart rate (bpm) 189 ± 10 
Note: MAS= maximal aerobic speed (km.h-1). RPE= rating of perceived exertion. 
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Table 2. Comparison on the dietary intake and macronutrient distribution between trials. 
24 h Dietary Intake  Trial 1 Trial 2 Trial 3 Trial 4 p 
CHO (g) 261.5 ± 118.3 276.9 ± 109.2 291.0 ± 122.6 283.6 ± 115.8 0.860 
PRO (g) 111.8 ± 52.8 134.3 ± 67.2 110.1 ± 49.6 114.0 ± 53.4 0.645 
FAT (g) 59.0 ± 25.3 70.7 ± 21.9 63.7 ± 31.0 66.5 ± 38.7 0.712 
Total Intake (kcal) 2169 ± 691 2365 ± 567 2264 ± 691 2197 ± 898 0.849 
      
CHO (g/kg) 3.4 ± 1.6 3.7 ± 1.6 3.8 ± 1.5 3.7 ± 1.4 0.895 
PRO (g/kg) 1.5 ± 0.6 1.7 ± 0.8 1.4 ± 0.6 1.5 ± 0.7 0.698 
FAT (g/kg) 0.8 ± 0.3 0.9 ± 0.2 0.8 ± 0.4 0.9 ± 0.5 0.759 
Total Intake 
(kcal/kg) 28.5 ± 8.2 31.2 ± 6.8 29.6 ± 8.0 28.8 ± 11.4 0.839 
Note: Total Intake (kcal) = Dietary Intake relative to body weight, CHO= carbohydrate; FAT= lipids; PRO= protein. 
 
For the 3000 m time-trial, the time in seconds was significantly less in the CAP compared to 
placebo condition (CAP = 893.9 ± 46.8 sec vs Placebo = 915.2 ± 67.6 sec, t = 2.939, p = 0.015) and 
there was a large effect size [d = 1.30, ∆% = -2.2 ± 2.5 (CI 95%= -3.7 to -0.6)]. 
 
In the 400 m time trial, the time in seconds was significantly less in the CAP compared to placebo 
condition (CAP = 66.4 ± 4.2 sec vs Placebo = 67.1 ± 4.8 sec, t = 2.250, p = 0.046) and the effect was 
very small [d = 0.16, ∆% = -1.0 ± 1.4% (CI 95%= -1.9 to -0.1)]. 
 
For the maximum heart rate (bpm) in the 3000 m (CAP = 189.3 ± 7.7 vs Placebo = 191.3 ± 5.9 
bpm, t = 1.044, p = 0.319) and 400 m (CAP = 7.4 ± 7.6 vs Placebo= 183.7 ± 6.6 bpm, t = -1.717, p = 
0.114) there were no statistically significant difference between conditions. The effect size was 
small for 3000 m [d = 0.30, ∆% = -1.0 ± 3.5% (CI 95%= -3.2 to 1.2)] and for 400 m there was a 
moderate effect [d = 0.52, ∆% = 2.4 ± 4.9% (CI 95%= -0.7 to 5.6)]. Figure 2 shows the differences 
in performance for the CAP and placebo condition. 
 
There was no statistically significant difference between conditions in RPE for the 3000 m time-
trial (CAP = 8.9 ± 1.1 vs Placebo = 8.6 ± 2.0, t = -0.804, p = 0.438) and the 400 m time-trial (CAP = 
9.1 ± 1.1 vs Placebo = 9.2 ± 1.0, t = 0.518, p = 0.615). The effect sizes were small for both 3000 m 
[d= 0.20, ∆%= 9.6 ± 30.5% (CI 95% = -9.8 to 29.0)] and 400 m [d = 0.10, ∆% = -1.4 ± 12.1% (CI 95% 
= -9.0 to 6.3)]. 
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Figure 2. Comparison between Capsaicin analog supplementation and placebo conditions on the performance. A 
= Maximum heart rate (bpm); B = Rating of perceived exertion (RPE); C = 400 m time-trial (seconds) and individual 
400 m time-trial; D = 3000 m time-trial (seconds) and individual 3000 m time-trial; CAP= Capsaicin analog 
supplementation (CAP= Capsiate); *= statistically significant difference between CAP and placebo conditions. 
 
DISCUSSION 
 
This is the first study to analyze the effects of Capsiate (CAP) supplementation on running time-
trial performance with two different distances. The main finding of this study was that acute 
CAP supplementation improved both 400 m and 3000 m running time-trial performances 
without modifying maximum heart rate or RPE in physically active adults.  
 
Currently, there are only two other studies investigating the effects of CAP supplementation on 
running performance. Recently, our group analyzed the effect of CAP supplementation (12 mg) 
on RPE, blood lactate concentrations, and performance during middle distance running (1500m) 
in physically active adults. The results demonstrated that CAP supplementation was effective 
to increase middle distance running performance (6). We also found that CAP supplementation 
increased the volume of work performed during four sets of back squat to fatigue with 70% of 
one-repetition maximum, and also a lower RPE (5). In contrast, Opheim and Rankin (18) did not 
find any significant time reduction after 15 x 30-m all-out sprints with 35-s rest intervals. 
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Collectively, these findings suggest that exercise type is an important factor with regard to the 
potential ergogenic benefits of CAP supplementation on exercise performance. The present 
study used the duration of time trials around ~1 min (400 m) and ~13-17 min (3000 m). 
Regarding our previous study, the duration of time-trial was around ~5-7 min (1500 m) (6) and 
approximately 45 seconds per set (70% 1RM squats to failure) (5). In contrast, the duration per 
sprint (30 m) in Opheim and Rankin (18) ranged from approximately 4.5 to 4.85 seconds between 
sprint 1 and 15, respectively. Considering the results of the present study, de Freitas et al. (6), 
and de Freitas et al. (5), it seems that CAP supplementation may have an ergogenic role 
according to the exercise duration, benefitting exercises that rely heavily on glycolysis. This 
study showed that CAP supplementation decreased time by 0.7 seconds during the 400 m 
running time-trial; however, the reduction was most meaningful in the 3000 m running time-
trial (21 sec). Interestingly, our previous study observed that CAP reduced ~5 seconds in 1500 
m running time-trial following CAP supplementation.  
 
Results from animal studies suggest that the benefits in running performance may be partially 
due to an increase in plasma free fatty acids and glycogen sparing brought about by increased 
epinephrine concentrations (10). Regarding the greater effect of CAP supplementation on 
middle distance running (3000m), we hypothesize that during the 3000 m trial there was greater 
glycogen depletion, which leads to a reduction in calcium release by the sarcoplasmic reticulum, 
and consequentially lowers muscle force production capacity. This would suggest that CAP 
supplementation is most effective during exercise protocols that rely heavily on glycolysis and 
reduces muscle glycogen, as CAP intake is associated with a glycogen sparing effect (9, 10). 
However, more studies are needed to substantiate this hypothesis in humans, and future 
research is necessary to investigate the ergogenic potential of CAP on longer duration endurance 
activities. 
 
Muscular fatigue is one of the limiting factors that affects running performance, as a result of 
lower calcium release by the sarcoplasmic reticulum, leading to reduced force production by 
skeletal muscle (1). The literature has shown that accumulation of hydrogen ions, inorganic 
phosphate, and glycogen depletion during exercise may reduce sarcoplasmic reticulum 
function, which leads to impairment in contraction efficiency and performance (20). Activation 
of TRPV1 in the skeletal muscle results in increased calcium release by the sarcoplasmic 
reticulum and potentially increases the interaction of actin-myosin filaments, resulting in greater 
force production (11). Thus, we believe that the greater myofiber force generation induced by 
CAP on the TRPV1 activation could enhance running economy. Supporting this hypothesis, 
Kazuya et al. (9) investigated the effects of acute CAP supplementation at a low (10 mg/kg body 
wt) and a high (100 mg/kg) dose on gastrocnemius muscle function and energetics during 6 min 
of repeated fatiguing isometric contractions in mice. This study found that CAP reduced the 
ATP cost during exercise with the higher dose also increasing force-generating capabilities in 
skeletal muscle. The lower energy cost of exercises suggests that CAP supplementation 
improves exercise economy. Our study showed that CAP increased running performance 
without modifying parameters of internal load (maximum heart rate and RPE). Based on these 
findings, acute CAP supplementation may also improve running performance by enhancing 
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movement economy, but further studies are necessary to measure the ATP costs of exercising 
with CAP supplementation. 
 
This study may be applied by coaches and trainers looking to improve middle distance (3000 m) 
running time-trial performance in physically active adults. In addition, some participants 
responded positively to the CAP while others did not, thus more studies should investigate 
whether single polynucleotide polymorphisms in the TRVP1 gene explain the individual 
responses (2). Despite the importance of this study, some limitations need to be mentioned. First, 
aerobic metabolism and metabolites (i.e. lactate) were not measured; second, we were unable to 
measure hydrogen ions, inorganic phosphate, glycogen depletion, calcium release, and 
catecholamine response. In addition, further studies are necessary to measure the metabolic and 
energy system contributions in humans. It is necessary to highlight that the administered form 
and dose of CAP in the present study was well-tolerated and none of the subjects reported 
gastrointestinal distress.  
 
Conclusions: In summary, acute capsaicin analog supplementation (Capsiate) improved 400 m 
and 3000 m running time-trial performance but without modifying the maximum heart rate or 
RPE in physically active adults. Furthermore, the present study showed a small improvement 
only in the performance during 3000 m time-trial, suggesting that CAP works better in middle 
distance rather than short distance (400 m) performances. 
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